68ga-dota-dpne
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 10, 2024 (NCT06411678)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 5'-nucleotidaseMODULATOR
NT5E modulator
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06844110 | N/A | Mar 1, 2025 | Chinese Academy of Medical Sciences |
| NCT06995976 | Early Phase 1 (Phase 1) | Mar 1, 2025 | Fujian Medical University |
| NCT06411678 | Early Phase 1 (Phase 1) | May 10, 2024 | Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 2 | 2 | 2024 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1